Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma

  title={Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma},
  author={I-Chia Lien and L. Horng and Pei-Lun Hsu and Chia-Ling Wu and Hui-Ching Sung and R. Wu},
  journal={Genes \& Cancer},
  pages={127 - 141}
Although new analogues of immunomodulatory drugs (IMiDs) are being developed for MM, the molecular mechanism of these drugs remains unclear. In the current study, we used MM cell lines as a model to investigate the molecular mechanism of thalidomide and to compare its potency with IMiDs such as pomalidomide. We determined that thalidomide did not inhibit cell proliferation of RPMI8226 and U266 MM cells, whereas pomalidomide showed a significant inhibitory effect on these two MM cell lines… Expand
Thalidomide targets EGFL6 to inhibit EGFL6/PAX6 axis-driven angiogenesis in small bowel vascular malformation
Cap-Independent Translation in Hematological Malignancies
More than just scanning: the importance of cap-independent mRNA translation initiation for cellular stress response and cancer
The mRNA Metabolism in Human Disease
Alternative Mechanisms of mRNA Translation Initiation in Cellular Stress Response and Cancer.
FGFs: crucial factors that regulate tumour initiation and progression


Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma.
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma
Drug Insight: thalidomide as a treatment for multiple myeloma